Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes.

類似資料

• Cardiovascular outcome trials of glucose-lowering strategies in type 2 diabetes--Authors' reply.
  著者:: Holman, R, 等
  出版事項: (2014)
• People at increased risk of cardiovascular disease screened for the NAVIGATOR trial frequently have undiagnosed diabetes or impaired glucose tolerance
  著者:: Califf, R, 等
  出版事項: (2003)
• Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.
  著者:: Califf, R, 等
  出版事項: (2008)
• Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease
  著者:: Green, J, 等
  出版事項: (2013)
• Rationale and design of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
  著者:: Bethel, M, 等
  出版事項: (2009)